Healthcare >> Analyst Interviews >> January 13, 2000

Emerging Pharamaceutical Companies : Corey Davis – Chase H&q

COREY DAVIS joined Hambrecht & Quist in 1997 covering the emerging pharmaceutical industry with an emphasis on mid-cap emerging pharma names like Alza, Forest, Shire, King, and Medicis. Mr. Davis also focuses on drug delivery and specialty firms like Emisphere and Neose. He also co-covers with Alex Zisson the big-cap pharmaceuticals such as Lilly, Schering-Plough, Merck, Pfizer, and Glaxo. Prior to joining H&Q, Mr. Davis received a PhD in Molecular Biology from Princeton University. He graduated Magna Cum Laude in 1991 with High Honors in Biology from Middlebury College, where he was elected to Phi Beta Kappa. Profile
TWST: What is it that distinguishes the specialty or emerging

pharmaceutical companies from the major pharmaceuticals apart from

market capitalization? How is the nature of the business